

Phenytoin

| | Accredited to ISO 15189:2012 |
|---|--|
| Synonyms | Epanutin |
| Clinical Indication | Phenytoin is a primary anticonvulsant for prophylaxis and treatment of partial and generalised tonic-clonic seizures. It is particularly appropriate where once daily dosing is an advantage. Main indications for monitoring are: |
| | On initiating therapy During I.V. therapy in status epilepticus Unexpected deterioration in seizure control As an adjunct to the diagnosis of toxicity When interacting drugs are added or withdrawn In pregnancy |
| | Drug Kinetics: Phenytoin is metabolised by the hepatic mixed-function oxidase system, which has a limited capacity and can become saturated at phenytoin concentrations within the target range. When levels are close to the saturation point a small increase in dose can result in a marked increase in serum concentration: this saturation point varies widely between patients. |
| | Toxicity : Symptoms of neurotoxicity (nausea, vomiting, tremor, and ataxia) are increasingly frequent as levels exceed 20 mg/L. |
| | Overdose: Following overdose and confirmation of toxicity there is not a case for continuous monitoring of levels to decide when to resume therapy. Phenytoin half-life is usually between 24 and 48 hours but due to the saturation kinetics, levels will gradually fall and then plummet i.e. half-life will be dependent on serum levels. Usually, phenytoin is stopped for 2 to 3 days and then the normal dose resumed. Serum levels should be monitored 7-10 days later after steady state has been obtained. An information sheet is available from National Poisons Service (Toxbase). |
| Part of Profile / See Also | |
| Request Form | Combined Pathology manual Blood form or ICE request. Please state dosage on request form. |
| Availability / Frequency of Analysis | On request during routine hours. Laboratory must be contacted regarding urgent requests. |
| Turnaround Time | Same day |
| Patient Preparation | Steady state levels. This is 4-5 days following a change in dose. |
| Sample Requirements | |
| Specimen Type | Serum and plasma |
| Volume | 2 ml |
| Acceptable Containers | Yellow top (SST) tube |

788



PF-PTD-246

| Green top (lithium-heparin) tube |
|--|
| paediatric orange top (lithium-heparin) |
| paediatric green top (lithium-heparin) |
| Plain serum samples may also be used. |
| Therapeutic range: 5 - 20 mg/L. |
| This range is indicative only, and some patients tolerate higher levels and require them to achieve effective control. Other patients are adequately |

require them to achieve effective control. Other patients are adequately controlled at lower concentrations and there is no need to use higher doses in such patients. Phenytoin is over 90% protein-bound in healthy adults on monotherapy, but

binding is substantially reduced in neonates, pregnancy, renal or hepatic disease. In such cases, effective or toxic free drug levels are obtained at lower total serum pheytoin levels.

To convert from μ mol/L to mg/L multiply by 0.253

| Interferences | |
|--------------------------------|--|
| Interpretation & Clinical | Critical phoning limit >25 mg/L |
| Decision Value (if applicable) | |
| References | Beckman kit insert |
| | Pathology Harmony Group, Clinical Biochemistry Outcomes, January 2011 (www. pathologyharmony.co.uk) |
| Test code | PHNY |
| Lab Handling | Analysed from primary tube and stored at 4°C. Serum and plasma samples stable for 7 days at 2-8°C. |

Reference Range & Units